Skip to Content

Abiraterone Pregnancy and Breastfeeding Warnings

Abiraterone is also known as: Yonsa, Zytiga

Medically reviewed by Last updated on Mar 13, 2020.

Abiraterone Pregnancy Warnings

Use is contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Risk Summary: Based on findings from animal studies and the mechanism of action, this drug is contraindicated for use in pregnant women because the drug can cause fetal harm and potential loss of pregnancy. This drug is not indicated for use in females.

-This drug can cause fetal harm based on its mechanism of action and animal studies.
-This drug is not indicated for use in women, and is contraindicated in women who are or may become pregnant.
-Based on findings in animal reproduction studies, male patients with female partners of reproductive potential should use effective contraception during therapy and for at least 3 weeks after the final dose.
-Based on animal studies, this drug may impair reproductive function and fertility in males of reproductive potential.

Animal studies revealed evidence of developmental toxicity at systemic exposures that were lower than in patients receiving the recommended human dose. Findings included embryofetal lethality, fetal developmental delay, decreased fetal body weight, urogenital effects, and maternal toxicity. Animal studies also showed this drug has potential to impair reproductive function and fertility in humans. Observed effects include atrophy, aspermia/hypospermia, reduced organ weights of the reproductive system, altered sperm morphology, and decreased fertility in males; increased pre-implantation loss and reduced number of corpora lutea, implantations, and live embryos in females. Fertility effects were reversible in female animals after 4 weeks and in male animals after 16 weeks from the last drug dose. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Abiraterone Breastfeeding Warnings

This drug is not indicated for use in women.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Zytiga (abiraterone)." Centocor Inc, Malvern, PA.
  2. "Product Information. Yonsa (abiraterone)." Sun Pharmaceutical Industries, Cranbury, NJ.

References for breastfeeding information

  1. "Product Information. Yonsa (abiraterone)." Sun Pharmaceutical Industries, Cranbury, NJ.
  2. "Product Information. Zytiga (abiraterone)." Centocor Inc, Malvern, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.